

1 **Genetics identifies obesity as a shared risk factor for co-occurring**  
2 **multiple long-term conditions.**

3 **Short title: Genetics pinpoints obesity as a shared risk factor between diseases**

4 Ninon Mounier <sup>1</sup>, Bethany Voller <sup>1</sup>, Jane AH Masoli <sup>1,2</sup>, João Delgado <sup>1</sup>, Frank Dudbridge <sup>3</sup>, Luke C  
5 Pilling <sup>1</sup>, Timothy M Frayling <sup>1,4</sup>, Jack Bowden <sup>1,5</sup>, on behalf of the GEMINI Consortium

6

7 **Affiliations**

- 8 1. Department of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences,  
9 University of Exeter, UK
- 10 2. Royal Devon University Healthcare NHS Foundation Trust, Barrack Road, Exeter, EX2 5DW, UK
- 11 3. Department of Population Health Sciences, University of Leicester, UK
- 12 4. Department of Genetic Medicine and Development, Faculty of Medicine, 1 rue Michel-  
13 Servet, CH-1211 Genève 4, Switzerland
- 14 5. Novo Nordisk Research Centre, Roosevelt Drive, Headington, Oxford, UK

15

16 **Corresponding author**

17 Prof Jack Bowden (J.Bowden2@exeter.ac.uk)

18

19

## 20 Abstract

21 **Background:** Multimorbidity, the co-occurrence of multiple long-term conditions (LTCs), is an  
22 increasingly important clinical problem, but often little is known about the underlying causes.  
23 Observational studies are highly susceptible to confounding and bias, and patients with multiple LTCs  
24 are usually excluded from randomised controlled trials. We investigate the role of a potentially critical  
25 multimorbidity risk factor, obesity, as measured by body mass index (BMI), in explaining shared  
26 genetics amongst 71 common LTCs.

27

28 **Methods and Findings:** In a population of northern Europeans, we estimated unadjusted pairwise  
29 genetic correlation,  $\hat{r}_g$ , between LTCs and partial genetic correlations after adjustment for the genetics  
30 of BMI,  $\hat{r}_{g|BMI}$ . We compared these correlations using a bespoke block-jackknife approach to assess  
31 whether differences between the estimates were statistically meaningful. We then used multiple  
32 causal inference methods to confirm that BMI causally affects not only individual LTCs, but also their  
33 co-occurrence. Finally, we attempted to quantify the population-level impact of intervening and  
34 lowering BMI on the prevalence of 15 key common multimorbid LTC pairs. Our results showed  
35 evidence that BMI partially explains some of the shared genetics for 740 LTC-pairs (30% of all pairs  
36 considered). For a further 161 LTC-pairs, the genetic similarity between the LTCs was entirely  
37 accounted for by BMI genetics. This list included diabetes and osteoarthritis:  $\hat{r}_g = 0.221$  ( $SE =$   
38  $0.021$ );  $\hat{r}_{g|BMI} = -0.019$  ( $SE = 0.030$ ), as well as those involving LTCs from the same broad family,  
39 or 'domain', such as gout and osteoarthritis:  $\hat{r}_g = 0.192$  ( $SE = 0.023$ );  $\hat{r}_{g|BMI} = 0.019$  ( $SE =$   
40  $0.029$ ). Causal inference methods confirmed that higher BMI acts as a common risk factor for a subset  
41 of these pairs, and therefore BMI-lowering interventions would reduce the prevalence of these pairs  
42 of LTCs. For example, we estimated that a 1 standard deviation or 4.5 unit decrease in BMI would  
43 result in 17 fewer people with both chronic kidney disease and osteoarthritis per 1000 who currently  
44 have both LTCs.

45

46 **Conclusions:** Our genetics-centred approach shows that obesity is an important mechanistic cause of  
47 many shared long-term conditions. We identify LTC pairs for which obesity is the predominating shared  
48 risk factor, and cases where it is one of the several shared risk factors involved. Our method for  
49 calculating full and partial genetic correlations is published as an R package *{partialLDSC}* for use by  
50 the research community.

51

52 **Key words**

53 Multiple long term conditions (MLTC); genetics; obesity; genetic correlation.

## 54 Introduction

55 Multimorbidity, defined as the coexistence of two or more long-term conditions (LTCs), is an important  
56 public health challenge. The prevalence of multimorbidity differs across geographic regions, age  
57 groups and between genders. It is also higher in more deprived individuals and is often associated with  
58 lower quality of life and increased healthcare costs [1]. Many observational studies have focused on  
59 defining and measuring multimorbidity [2,3]. However, disparate definitions have led to variations in  
60 its characterisation [4]. For example, a thorough definition of chronicity and a list of chronic LTCs have  
61 been proposed by [5] and new approaches to cluster LTCs and identify patterns of multimorbidity have  
62 been developed [6,7]. These approaches have limitations, as they often involve single datasets and  
63 modalities, and cluster identification might differ depending on the algorithm [8].

64 Investigating the role of common epidemiological risk factors for multimorbidity is vitally important,  
65 as it can provide a better understanding of the mechanisms underlying the co-occurrence of LTCs and  
66 help to develop efficient prevention strategies. For example, using observational data to study the  
67 relationship between socio-economic status and multimorbidity, it has been shown that lower  
68 education level and higher deprivation were associated with increasing risk of multimorbidity [9]. A  
69 large multi-cohort prospective study provided evidence of associations between obesity and a wide  
70 range of LTCs, as well as with the number of LTCs developed, highlighting the potentially important  
71 role of obesity in multimorbidity [10].

72 We have previously assessed the genetic similarity between 2546 pairs of LTCs [11], allowing us to re-  
73 examine associations from observational epidemiology. Using genetic predictors of a trait, rather than  
74 observational measures, reduces the impact of inherent issues such as confounding, measurement  
75 error and reverse causation [12]. These issues are particularly problematic for studies of  
76 multimorbidity. Over the last decade, genetic approaches have also greatly benefited from the increase  
77 in sample sizes, and methods that enable data from more than one cohort to be incorporated into the  
78 analysis, enabling researchers to work with data linking tens of thousands of cases for common LTCs  
79 from a large range of health exposures. This genetics-centred approach has been used to estimate the  
80 costs of obesity on healthcare systems [13]. Our previous work showed evidence of widespread  
81 genetic correlation across LTCs, with obesity being highly genetically correlated with a broad range of  
82 LTCs [11]. Depending on context, obesity can be considered a risk factor for multiple LTCs or an LTC in  
83 its own right. In this work, we focus on using statistical genetics methods to quantify the role of obesity  
84 as a common risk factor for multimorbidity.

85 Genetic correlation is driven by pleiotropy, when a genetic locus affects several traits, and can reflect  
86 different scenarios: a direct relationship between the two traits (vertical pleiotropy – when the two

87 traits are part of a causal cascade), a common biological process or the effect of a common risk factor  
88 on both traits (horizontal pleiotropy – when the two traits have no direct effect on each other) [14]  
89 (Supplementary Figure 1). Often, genetic correlations are driven by a combination of both vertical and  
90 horizontal pleiotropy [15]. We propose an approach to help differentiate these mechanisms in  
91 multimorbidity, focussing on obesity as a well-known risk factor for several long-term conditions [16].  
92 We chose the most common, general clinical measure of obesity for this investigation: body mass index  
93 (BMI).

94 We use data from the GEMINI collaborative for 71 long-term common LTCs comprising 2485 distinct  
95 pairs. We propose an approach to compare pairwise unadjusted genetic correlations to partial genetic  
96 correlations that accounts for BMI genetics, formally testing whether BMI explains a portion of the  
97 genetic correlation for a given LTC pair. We also applied causal inference methods to elucidate the  
98 causal (biological) mechanisms through which BMI affects the genetic correlation between LTCs,  
99 quantifying its pivotal role as a common risk factor in multimorbidity.

## 100 **Methods**

### 101 - **Data resources**

102 We used GWAS summary statistics, derived from individuals of European descent, for 71 common and  
103 heritable LTCs, encompassing 13 distinct disease domains, grouped according to the International  
104 Classification of Disease (ICD): such as cardiovascular or respiratory domains [17]. These GWAS data  
105 are described in detail in [11]; relevant diagnostic and analytical code is available on the project GitHub  
106 pages [<https://github.com/GEMINI-multimorbidity>]. LTCs were defined by adapting existing diagnostic  
107 code lists with input from clinical experts. LTCs were selected for genetic analyses if reaching a  
108 prevalence greater than 0.5% in people over 65 in each of two large population-based cohorts in the  
109 UK and Spain [18,19]. *Heritability* measures the proportion of phenotypic variance explained by  
110 genetics. We estimated this in UK Biobank [20] to identify a subset of LTCs with a genetic basis. Finally,  
111 for each condition, we used the largest sample size available by combining GWAS data from up to three  
112 sources: UK Biobank, FinnGen, and condition specific consortium data (details available in  
113 Supplementary Table 1). For many of these LTCs, the meta-analysed data used represents the largest  
114 sample size used to date. We refer to these meta-analysed GWAS summary statistics as "GEMINI  
115 summary statistics" for the rest of the paper.

116 We also used two different sets of GWAS summary statistics for BMI. First, we used the largest data to  
117 date ( $N \approx 700,000$ ), combining results from the GIANT Consortium and UK Biobank [21], to estimate  
118 partial genetic correlations. We also used earlier results from the GIANT Consortium ( $N \approx 340,000$  –  
119 minimal overlap with the GEMINI summary statistics) [22], to perform causal inference analyses, after  
120 ensuring that the partial genetic correlations results were consistent with the ones obtained using the  
121 larger dataset.

122 The GWAS summary statistics for the 71 LTCs, as well as BMI, were pre-processed using the munging  
123 function from the LD-score regression (LDSC) [23] and for all LDSC analyses we used LD-scores  
124 estimated from the 1000G EUR reference panel.

### 125 - **Covariance and correlation**

126 *Covariance* measures the extent to which the observed value of one quantity predicts the value of  
127 another quantity. For example, in the case of two such quantities – osteoarthritis (OA) and type 2  
128 diabetes (T2D) diagnoses in a study population - a positive covariance would indicate that having T2D  
129 increases the probability of having OA. *Correlation* is simply a scaled version of covariance that lies  
130 between -1 and 1. If all individuals in a population with T2D also have OA, the two would have a

131 correlation of 1. If all individuals in a population with T2D do not have OA, the two would have a  
 132 correlation of -1.

133 - **Partial genetic covariance and correlation**

134 In this paper we extensively study the genetic covariance and correlation between two LTCs. That is,  
 135 the degree to which genetic variants that predict one LTC also predict the other LTC. Furthermore, we  
 136 focus on understanding how the genetic covariance between two LTCs changes when we remove the  
 137 genetic effects of a common risk factor.

138 Using the Schur complement, the partial (or ‘adjusted’) genetic covariance between LTCs  $k$  and  $l$   
 139 ( $\hat{\rho}_{g\{k,l|x\}}$ ), which corresponds to their genetic covariance while holding the genetic effects of the trait  
 140  $x$  (in our case, BMI) constant, can be defined as follows:

$$\hat{\rho}_{g\{k,l|x\}} = \hat{\rho}_{g\{k,l\}} - \frac{\hat{\rho}_{g\{k,x\}} * \hat{\rho}_{g\{x,l\}}}{\hat{h}_{\{x\}}^2}, \quad (1)$$

where  $\hat{\rho}_{g\{k,l\}}$  is the genetic covariance between condition  $l$  and  $k$ ,  
 $\hat{\rho}_{g\{k,x\}}$  is the genetic covariance between condition  $k$  and trait  $x$ ,  
 $\hat{\rho}_{g\{x,l\}}$  is the genetic covariance between trait  $x$  and condition  $l$ ,  
 $\hat{h}_{\{x\}}^2$  is the heritability estimate for trait  $x$ .

141

142 Genetic covariance and heritability estimates were obtained from GWAS summary statistics using  
 143 cross-trait LD Score regression (LDSC), as previously described by [24].

144 Similarly, the partial heritability for LTCs  $k$  and  $l$  ( $\hat{h}_{\{k|x\}}^2$  and  $\hat{h}_{\{l|x\}}^2$ , respectively) can be estimated:

$$\begin{aligned} \hat{h}_{\{k|x\}}^2 &= \hat{h}_{\{k\}}^2 - \frac{\hat{\rho}_{g\{k,x\}} * \hat{\rho}_{g\{x,k\}}}{\hat{h}_{\{x\}}^2}, \\ \hat{h}_{\{l|x\}}^2 &= \hat{h}_{\{l\}}^2 - \frac{\hat{\rho}_{g\{l,x\}} * \hat{\rho}_{g\{x,l\}}}{\hat{h}_{\{x\}}^2}, \end{aligned} \quad (1)$$

where  $\hat{h}_{\{k\}}^2$  is the heritability estimate for condition  $k$ ,  
 $\hat{h}_{\{l\}}^2$  is the heritability estimate for condition  $l$ .

145

146 Finally, the (unadjusted) genetic correlation ( $\hat{r}_{g\{k,l\}}$ ) and the partial genetic correlation ( $\hat{r}_{g\{k,l|x\}}$ )  
 147 between LTCs  $k$  and  $l$  can be derived:

$$\hat{r}_{g\{k,l\}} = \frac{\hat{\rho}_{g\{k,l\}}}{\sqrt{\hat{h}_{\{k\}}^2 \hat{h}_{\{l\}}^2}},$$
$$\hat{r}_{g\{k,l|x\}} = \frac{\hat{\rho}_{g\{k,l|x\}}}{\sqrt{\hat{h}_{\{k|x\}}^2 \hat{h}_{\{l|x\}}^2}}.$$
(2)

148

149 To test if the partial (or adjusted) genetic correlation estimate is different from the unadjusted genetic  
150 correlation estimate, the following test statistic was used:

$$t_{\{k,l\}} = \frac{\hat{r}_{g\{k,l\}} - \hat{r}_{g\{k,l|x\}}}{\sqrt{\text{Var}(\hat{r}_{g\{k,l\}}) + \text{Var}(\hat{r}_{g\{k,l|x\}}) - 2\text{Cov}(\hat{r}_{g\{k,l\}}, \hat{r}_{g\{k,l|x\}})}}.$$
(3)

151

152 The variance of the unadjusted genetic correlation ( $\text{Var}(\hat{r}_{g\{k,l\}})$ ), the variance of the partial genetic  
153 correlation ( $\text{Var}(\hat{r}_{g\{k,l|x\}})$ ) and the covariance between the two ( $\text{Cov}(\hat{r}_{g\{k,l\}}, \hat{r}_{g\{k,l|x\}})$ ) were  
154 obtained using a novel block-jackknife approach (see details in Supplementary Note 1). This enabled  
155 us to rigorously test for a difference between the two, for the first time.

156 We estimated partial genetic correlations between all pairs of LTCs, using two different sets of GWAS  
157 summary statistics for BMI [21,22]. False discovery rate (FDR) correction ( $Q - \text{value} < 0.05$ ) was  
158 applied for both unadjusted and partial genetic correlations, and the differences between the two, to  
159 account for multiple testing. LTC pairs were then first classified according to the difference between  
160 the two (FDR-corrected statistically significant difference or not). Significant LTC pairs were then  
161 further classified into four categories:

- 162 • Both unadjusted and partial genetic correlations were statistically non-significant (FDR of 5%);
- 163 • Both unadjusted and partial genetic correlations were statistically significant;
- 164 • Only unadjusted genetic correlations were statistically significant;
- 165 • Only partial genetic correlations were statistically significant.

166 Here, we focus on the results with evidence of genetic similarity before and/or after adjustment for  
167 BMI. LTC pairs were defined as *within-domain*, if both LTCs belong to the same disease domain, or  
168 *cross-domain*, if the two LTCs belong to different disease domains.

169 Our analysis pipeline has been implemented in a R package - `partialLDSC` - and is available on GitHub  
170 [<https://github.com/GEMINI-multimorbidity/partialLDSC>]. All analyses have been performed using  
171 version 0.1.0.



## 172 - Causal inference using Mendelian randomization

173 To better understand the causal relationship between BMI and each individual LTC, we performed two-  
174 sample Mendelian Randomization (MR) analyses. MR is a causal inference method that uses genetic  
175 variants as instrumental variables to estimate the causal effect of an exposure on an outcome. We  
176 used it to estimate the causal effect of intervening to lower BMI on each individual LTC (Supplementary  
177 Figure 2, Supplementary Note 2).

## 178 Removing BMI causal effect from genetic correlations

179 For LTCs found to be strongly causally affected by BMI (23 LTCs, Supplementary Note 2), we used a  
180 recently proposed Bayesian GWAS approach to derive direct effect estimates [25,26]. The direct effects  
181 were estimated by taking out the causal effect of BMI from the observed association effect between  
182 each genetic variant and the condition. They correspond to the direct association between genetic  
183 variants and the condition, not via the BMI pathway, and can be seen as BMI-corrected GWAS summary  
184 statistics. We ran the analysis for each condition using the bGWAS R-package ([https://github.com/n-](https://github.com/n-mounier/bGWAS-version-1.0.3)  
185 [mounier/bGWAS - version 1.0.3](https://github.com/n-mounier/bGWAS-version-1.0.3)) [25], selecting instruments for BMI using a p-value threshold of  $5 \cdot 10^{-8}$   
186 with default values used for other parameters. We then used the summary statistics for the direct  
187 effects to re-estimate genetic correlations (denoted as bGWAS genetic correlations,  $\hat{r}'_{g\{k,l\}}$ ) for 253  
188 pairs. We only reported the results for the 246 pairs for which we detected a statistically significant  
189 difference between the unadjusted and the partial genetic correlation estimates. We then compared  
190 partial genetic correlations to bGWAS genetic correlations to understand if the difference between  
191 unadjusted and partial genetic correlations are likely to be driven by the causal effect of BMI on LTCs,  
192 or solely by the correlation between BMI and the LTCs, which could be due to other mechanisms.

## 193 Estimating the causal effect of BMI on co-occurrence of LTCs and estimating the effect of intervening 194 on BMI

195 To further understand the role of BMI in the co-occurrence of LTCs, we carried out additional analyses  
196 for the 15 pairs with the strongest difference, and no evidence of genetic correlation, after adjusting  
197 for BMI. First, we performed an additional GWAS in UK Biobank, defining cases for our analyses as  
198 individuals having been diagnosed with **both** LTCs (Supplementary Note 3). These GWAS summary  
199 statistics were then used to estimate the causal effect of BMI on the co-occurrence of each pair, using  
200 the same MR approach as for individual LTCs (Supplementary Note 2). The genetic associations used  
201 for MR are in standard deviation units for BMI (<https://gwas.mrcieu.ac.uk/datasets/ieu-a-835/>, 1SD =  
202 4.77), and are log odds ratios for the outcomes. Therefore, for each pair  $p$ , the causal effect estimate  
203  $\hat{\beta}_p$  represents log odds ratios per 1 standard deviation ( $\sigma$ ) increase in the BMI on the pair, compared  
204 to the actual observed BMI in the sample ( $\bar{\mu}$ ):

$$\hat{\beta}_p = \log \left( \frac{\text{odds } P = 1 \mid BMI = \bar{\mu} + \sigma}{\text{odds } P = 1 \mid BMI = \bar{\mu}} \right) \quad (4)$$

205

206 This causal effect estimate can then be used to evaluate how intervening to lower BMI would affect  
207 the number of people having both LTCs [27]. In practice, for each pair, we estimated the reduction in  
208 1000 individuals ( $\hat{R}_p$ ) of reducing BMI by 1 SD:

$$\hat{R}_p = 1000 \cdot \left( \hat{\pi}_p - \frac{\hat{\beta}_p \hat{\pi}_p}{(1 - \hat{\pi}_p + \hat{\beta}_p \hat{\pi}_p)} \right), \quad (5)$$

where  $\hat{\pi}_p$  is the observed prevalence for pair  $p$ ,

209 using this risk reduction as the basis for further calculations. We used it to derive the number of cases  
210 that could be prevented from each pair following a hypothetical intervention in the sample used for  
211 our genetic analyses and estimated the impact on the prevalence of such an intervention.

212 **Results**

213 **BMI plays an important role in explaining genetic correlations between common long-term**  
 214 **conditions.**

215 From the 2485 pairs defined from the 71 LTCs, we detected a statistically significant difference when  
 216 adjusting for BMI genetics for 1362 pairs (Table 1, Supplementary Table 2). These pairs encompassed  
 217 64 out of 71 LTCs. For most of these pairs (1078/1362), the partial genetic correlation estimates were  
 218 weaker than the unadjusted ones, reflecting an attenuation of the genetic correlation when adjusting  
 219 for BMI genetics.

220 Table 1

221

	$\hat{r}_g$ ( $Q - value \geq 0.05$ )	$\hat{r}_g$ ( $Q - value < 0.05$ )
$\hat{r}_{g BMI}$ ( $Q - value \geq 0.05$ )	308	161
$\hat{r}_{g BMI}$ ( $Q - value < 0.05$ )	33	860


222 *Description of the 1362 pairs with statistically significant differences ( $Q - value < 0.05$  for the test statistics*  
 223 *described in Equation 4), according to the statistical significance of unadjusted ( $\hat{r}_g$ ) and partial ( $\hat{r}_{g|BMI}$ ) genetic*  
 224 *correlation estimates.*

225

226 In most of the pairs (860/1362) for which a statistically significant difference was observed, we found  
 227 evidence of shared genetics both before and after adjusting for BMI, indicating that while BMI  
 228 influences the genetic correlation for these pairs, it does not account for all of it. These include 131  
 229 *within-domain* pairs, and 769 *cross-domain* pairs, many of them encompassing LTCs from the “diseases  
 230 of the circulatory system”, but also from the “diseases of the skin and subcutaneous tissue” and the  
 231 “diseases of the digestive system” domains. For most of these pairs, the partial genetic correlation  
 232 estimates were smaller (740/860). The majority of the 120 pairs where the partial genetic correlation  
 233 estimates were larger were related to anxiety disorder (30), osteoporosis (27), schizophrenia and  
 234 delusional disorders (12), as well as tinnitus (11). The unadjusted and the partial genetic correlation  
 235 estimates for the 20 pairs of these 860 with the strongest difference are presented in **Error! Reference**  
 236 **source not found.** Amongst these 20 top pairs, 12 distinct LTCs are represented, with some conditions  
 237 common between pairs with cholelithiasis in 6 pairs and carpal tunnel syndrome, gout and chronic  
 238 kidney disease in 7 pairs. This illustrates that BMI genetics tends to explain a larger proportion of  
 239 genetic correlation in pairs that contain specific LTCs. Furthermore, these LTCs are also amongst the

240 ones with the strongest genetic correlations with BMI (Supplementary Table 1), and most strongly  
 241 causally affected by BMI in our MR results (Supplementary Note 2). For 471 of these 860 pairs, our MR  
 242 analysis showed that BMI is likely causal for both LTCs, providing further evidence that BMI is the likely  
 243 source of the genetic correlation.

244 Figure 1




245  
 246 *Unadjusted (blue circle) and partial (blue-green triangle) genetic correlation estimates and 95% confidence*  
 247 *intervals for the 20 pairs with the strongest difference (Q – value indicated for each pair on the right) and*  
 248 *evidence of shared genetics both before and after adjusting for BMI.*

249  
 250 For more than 10% of the pairs with a significant difference (161/1362), we showed that BMI is likely  
 251 to account for a substantial component of the genetic correlation. For these pairs, BMI adjustment  
 252 resulted in a greatly reduced partial genetic correlation estimate consistent with no remaining genetic  
 253 similarity between the two LTCs. Many of these pairs (76/161) included at least one condition from  
 254 the “*diseases of the circulatory system*” domain, and almost all the pairs were *cross-domain* pairs  
 255 (154/161) for example 24 pairs had one condition from the “*diseases of the circulatory system*” domain,  
 256 and one condition from the “*diseases of the musculoskeletal system and connective tissue*” domain.

257 For instance, we observed complete attenuation of the genetic correlation between: type 2 diabetes  
 258 and osteoarthritis ( $\hat{r}_g = 0.2216$  ( $SE = 0.0208$ );  $\hat{r}_{g|BMI} = -0.0189$  ( $SE = 0.0296$ )); gout and  
 259 osteoarthritis ( $\hat{r}_g = 0.1920$  ( $SE = 0.0229$ );  $\hat{r}_{g|BMI} = 0.0191$  ( $SE = 0.0292$ )); and gout and sleep  
 260 apnoea ( $\hat{r}_g = 0.2313$  ( $SE = 0.0266$ );  $\hat{r}_{g|BMI} = 0.0118$  ( $SE = 0.0355$ )) (Supplementary Table 2,  
 261 [Figure 2](#)). For 93 of these pairs, including all the ones in Figure 2, our MR analysis detected a statistically  
 262 significant causal effect of BMI on both LTCs.

263

264 [Figure 2](#)



265


266 *Unadjusted (blue circle) and partial (blue-green triangle) genetic correlation estimates and 95% confidence*  
 267 *intervals for the 10 pairs with the strongest difference (Q – value indicated for each pair on the right) and*  
 268 *evidence of shared genetics only before adjusting for BMI.*

269

270 For 33 LTC pairs, there was no evidence (at FDR <0.05) of genetic correlation, but on adjustment for  
 271 the genetics of BMI, a residual genetic effect was observed (Supplementary Table 2, [Figure 3](#)). These  
 272 results are consistent with BMI masking shared genetic mechanisms between the two LTCs. Most of  
 273 these pairs were cross-domain pairs (28/33) and notably, 14 of these pairs were related to  
 274 osteoporosis. This can be explained by the fact that lower BMI has been shown to be associated with  
 275 higher osteoporosis risk [28] whereas for most other LTCs, higher BMI is suspected to be risk increasing.  
 276 This is further supported by our MR analysis, as we found a statistically significant causal effect of lower  
 277 BMI on osteoporosis (Supplementary Note 2). For 19 of these pairs, our MR results showed that BMI  
 278 is likely causal for both LTCs, but protective for one of them, consistent with the partial genetic  
 279 correlation being stronger than the unadjusted genetic correlation.

280

281 *Figure 3*



282

283 *Unadjusted (blue circle) and partial (blue-green triangle) genetic correlation estimates and 95% confidence*  
 284 *intervals for the 10 pairs with the strongest difference (Q – value indicated for each pair on the right) and*  
 285 *evidence of shared genetics only after adjusting for BMI.*

286

287 For 1123 LTC pairs, adjusting for BMI genetics had no statistically significant effect on the genetic  
 288 correlation between them, suggesting that other mechanisms are giving rise to the genetic similarity  
 289 between these LTCs. For example, the strong genetic correlation between allergic rhinitis and bursitis  
 290 ( $\hat{r}_g = 0.3640$  ( $SE = 0.0777$ );  $\hat{r}_{g|BMI} = 0.3639$  ( $SE = 0.0795$ ); difference  $Q - value = 0.98$ ), or  
 291 between anxiety and schizophrenia ( $\hat{r}_g = 0.4417$  ( $SE = 0.0234$ );  $\hat{r}_{g|BMI} = 0.4414$  ( $SE =$   
 292  $0.0232$ ); difference  $Q - value = 0.91$ ), remain similar after adjusting for BMI genetics.

293 These results were consistent with those obtained using less recent BMI data, excluding UK Biobank,  
 294 with partial correlation estimates that were highly similar (correlation = 0.9974, Supplementary  
 295 Figure 3-A), with evidence of the analysis using the more recent data being more powered  
 296 (Supplementary Table 3, Supplementary Table 4, Supplementary Figure 3-B).

### 297 **BMI acts as a common risk factor in multimorbidity**

298 To compare our partial genetic correlations to another method (bGWAS) we estimated pairwise  
 299 genetic correlations accounting for the estimated causal effect of BMI on *both* LTCs, for 246 pairs. We  
 300 studied the 23 LTCs that were strongly causally affected by BMI and a subset of LTC pairs for which a  
 301 statistically significant difference between unadjusted and partial genetic correlation estimates were  
 302 observed. We used bGWAS to take out the causal effect of BMI on each individual LTC and re-estimated  
 303 pairwise genetic correlations. These differ from the partial correlation estimates since they only  
 304 remove the BMI genetics estimated to be due to the causal role of BMI on each condition. We observed

305 a strong agreement between the partial genetic correlation estimates and the bGWAS correlation  
306 estimates, with some of the bGWAS genetic correlation estimates being stronger (less attenuated) than  
307 the partial ones (Supplementary **Error! Reference source not found.**-A, Supplementary Table 5),  
308 suggesting that partial genetic correlation estimates might capture additional associations between  
309 BMI and the LTCs that are not due to these causal relationships. See Supplementary Note 4 for details.

310 For a subset of pairs, the 15 pairs with the strongest difference and no evidence of genetic correlation  
311 after adjusting for BMI genetics, we performed genetic analysis for each pair and further investigated  
312 the role of BMI using MR results. We showed that higher BMI had a strong risk-increasing causal effect  
313 on every condition within these pairs. In addition, the unadjusted genetic correlation estimates were  
314 all positive, and higher BMI was shown to be risk increasing for all LTCs (Supplementary Table 6). This  
315 suggests that the attenuation of the genetic correlation is likely due to BMI acting as common risk  
316 factor. This is further confirmed by the MR analysis on the pairs, with all causal effect estimates being  
317 positive and statistically significant ( $p - value < 0.05/64$ , Bonferroni correction) (Supplementary  
318 Table 6).

319 For these pairs with directionally consistent individual causal effects, we also estimated how  
320 intervening on BMI would affect the number of people having **both** LTCs. To do so, we calculated the  
321 reduction in the number of cases for 1000 individuals expected by a one SD BMI reduction. Results  
322 were highly correlated with the observed prevalence of the pairs in our sample and lowering BMI had  
323 a stronger effect on pairs with higher prevalence (Supplementary Table 6). Results for the 5 pairs with  
324 a prevalence above 1% are presented in [Table 2](#). For example, 16 out of 1000 people having both  
325 chronic kidney disease and osteoarthritis, and 9 out of 1000 people having both type 2 diabetes and  
326 osteoarthritis, would not have both LTCs after a one SD BMI intervention (1SD = 4.77). In the UK  
327 Biobank sample used for our analysis, this would translate into a 4.6% reduction in prevalence for the  
328 co-occurrence of chronic kidney disease and osteoarthritis, and 3.3% reduction in prevalence for the  
329 co-occurrence of type 2 diabetes and osteoarthritis. We postulate that the impact of such an  
330 intervention in the general population is likely to be stronger, since the prevalence of these pairs of  
331 LTC in UK Biobank is lower than in the general population (Supplementary Table 6), due to healthy  
332 volunteer bias in UK Biobank [29].

333

334 *Table 2*  
335

condition 1	condition 2	$\hat{r}_g$ (SE)	$\hat{r}_{g BMI}$ (SE)	$\hat{\beta}_{IVW}$ (SE ; <i>p</i> - value)	$\hat{R}$	$\pi$ UK Biobank	$\hat{\pi}_R$ UK Biobank
Chronic Kidney Disease	Osteoarthritis	0.1356 (0.0330)	0.0202 (0.0359)	0.38 (0.0835 ; 4.2e-06)	16.76	2.752	2.706
Diabetes Type 2	Osteoarthritis	0.2216 (0.0208)	-0.0189 (0.0296)	0.71 (0.1820 ; 9.4e-05)	9.69	3.434	3.401
Cholelithiasis	Osteoarthritis	0.2110 (0.0295)	0.0538 (0.0323)	0.63 (0.0775 ; 6.0e-16)	8.83	2.406	2.385
Asthma	Chronic Kidney Disease	0.0829 (0.0353)	0.0158 (0.0361)	0.35 (0.1132 ; 2.1e-03)	7.10	1.092	1.085
Gout	Osteoarthritis	0.1920 (0.0229)	0.0191 (0.0292)	0.61 (0.0963 ; 3.2e-10)	6.47	1.657	1.646

336 *Mendelian randomization and BMI intervention results for 5 pairs with a prevalence above 1% in our sample.*  
337 *For each pair of LTC (condition 1 and condition 2), the unadjusted genetic correlation estimate and standard*  
338 *error ( $\hat{r}_g$ ), the partial genetic correlation estimate and standard error ( $\hat{r}_{g|BMI}$ ), as well as the causal effect*  
339 *estimate ( $\hat{\beta}_{IVW}$ ), its standard error and the corresponding *p*-value, of BMI on the pair, and the reduction in the*  
340 *number of cases with both LTCs when reducing BMI by one SD for 1000 individuals ( $\hat{R}$ ), and the prevalence of*  
341 *cases with both LTCs in percentage in UK Biobank before ( $\pi$  UK Biobank) and after an hypothetical intervention*  
342 *( $\hat{\pi}_R$  UK Biobank), are reported.*

343



## 344 Discussion

345 Clinical trials and Mendelian randomization studies have shown that obesity is very likely to cause  
346 many individual LTCs [30]. However, the role of higher BMI in the co-occurrence of two LTCs and the  
347 extent to which it accounts for some, or all of the co-occurrence is less certain. In this study we  
348 combined genetics data from very large studies with a novel statistical analysis technique to estimate  
349 the extent to which higher BMI influences the genetic similarity between pairs of LTCs. Our analyses  
350 indicated that for a large proportion of pairs of LTCs, higher BMI is likely to explain part of the genetic  
351 correlation, but that other factors are likely to also contribute. For 55% of LTC-pairs tested we observed  
352 a change in the genetic correlations when accounting for BMI genetics. Using causal inference  
353 methods, we confirmed that BMI acts as a common risk factor for a subset of these pairs, and that  
354 intervening on BMI could help reduce the prevalence of pairs of multimorbid LTCs.

355 Our analyses indicated that for 36% (740/2485) of LTCs pairs we studied, higher BMI could explain a  
356 significant proportion of their genetic correlation. Of these, 161 pairs were identified for which the  
357 estimates were consistent with a null partial genetic correlation, suggesting that the genetic similarity  
358 between these pairs of LTCs is *entirely* explained by the BMI. These included many pairs that spanned  
359 traditional disease domains, especially those involving osteoarthritis and metabolic diseases, and  
360 COPD and metabolic diseases. For some of these pairs, previous studies have observed a similar strong  
361 attenuating effect of BMI, such as for type 2 diabetes and osteoarthritis and gout and sleep apnoea  
362 [31,32].

363 Thirty-three pairs (about 1%) of LTCs showed no evidence of unadjusted genetic similarity, but after  
364 accounting for the genetic effect of BMI, a partial genetic correlation emerged. These results suggest  
365 that shared genetic causes may exist for some pairs, but they could be masked by BMI having effects  
366 in opposite directions. Most of these pairs were related to osteoporosis, which may be explained by  
367 the fact that the direction of the effect of BMI on osteoporosis is opposite to the one on most other  
368 LTCs [33]. We observed for example a positive genetic correlation between osteoporosis and stroke,  
369 only after accounting for BMI genetics. Because genetic risk usually reflects life-long exposure, this  
370 correlation suggests the presence of shared risk factors for osteoporosis and metabolic traits, although  
371 we cannot rule out a genetic correlation resulting from reduced mobility and bone load reduction in  
372 stroke patients [34].

373 Our results corroborate the role of BMI acting as a common risk factor for various pairs of LTCs. We  
374 have used causal inference approaches to test the causal relationship between BMI and the different  
375 LTCs, and we used the bGWAS approach to re-estimate genetic correlation estimates, adjusting only

376 for the part of the genetic correlation that is driven by the causal effect of BMI on the LTCs. Overall, we  
377 observed a strong agreement between partial and bGWAS genetic correlation estimates, providing  
378 further evidence that BMI does act as common risk factor. However, the bGWAS genetic correlation  
379 estimates were in general stronger, suggesting that the correlation between BMI and the LTCs is not  
380 entirely explained by the causal effect and that more complex relationships may exist. In addition, the  
381 effects derived from bGWAS would only capture linear causal effects, so any non-linear effects would  
382 not be accounted for, possibly explaining why the bGWAS genetic correlations estimates were stronger.  
383 We also showed that BMI has a strong, risk-increasing, causal effect on some pairs of LTCs, and that  
384 lowering BMI could help reduce the prevalence of these pairs.

385 Many of the LTC pairs include those from across traditional clinical domains, and for a majority of these  
386 pairs, the attenuation after accounting for BMI was as strong as that for within-domain pairs. For  
387 example, based on our genetic approach, the role of BMI in explaining the co-occurrence of COPD and  
388 several metabolic LTCs and osteoarthritis and several metabolic LTCs, is just as strong as the role of  
389 BMI in explaining the co-occurrence of two metabolic LTCs. The reasons for these findings require  
390 further investigation but our results suggest that interventions aimed at weight loss should monitor  
391 these additional LTCs more closely, or conversely, patients with a combination of obesity and a  
392 metabolic condition should be monitored for less obvious non-metabolic LTCs.

393 The definition of obesity, and other obesity-related measures and phenotypes that can be used as  
394 proxies in public health research, is critical [35] and which one is the best predictor for disease risk  
395 might depend on the condition [36–42]. For that reason, we believe that results using BMI, as a  
396 continuous phenotype that can be easily measured in the general population, are less likely to be  
397 biased and are easier to interpret. Further analyses, to better understand how exactly BMI affects each  
398 condition could be performed, using clustering-based MR approaches for instance [43]. Other obesity-  
399 related phenotypes should be used to investigate the effect of body fat distribution, like waist-to-hip  
400 ratio for example, and these analyses would benefit from a sex-specific approach, to better account  
401 for the known sex-specific genetic architecture of such phenotypes [44,45].

402 This work focused on individuals of European descent, mostly because of data availability, and analyses  
403 are needed in other ethnic groups, as it is known that both BMI distribution [46] and its effect on LTCs  
404 may vary depending on ethnicity [47,48], to further understand the role of BMI in multimorbidity in  
405 these groups. It is important to note that the relative paucity of data from people of non-European  
406 ancestry has a disproportionately large effect on the utility of genetics for multimorbidity, because  
407 missing data from only one condition will affect multiple pairs.

408 This work not only has important implications for research that aims at identifying shared biological  
409 pathways between pairs of LTCs but also has direct implications for potential intervention. We showed  
410 that intervening on BMI would directly impact the prevalence of pairs of LTCs, such as type 2 diabetes  
411 and chronic kidney disease, or type 2 diabetes and osteoarthritis. This is particularly important with  
412 the recent commercialisation of weight loss drugs that could be used to reduce the co-occurrence of  
413 LTCs through a better weight management strategy. This work focused on individuals of European  
414 descent, mostly because of data availability, and analyses are needed in other ethnic groups, as it is  
415 known that both BMI distribution [46] and its effect on LTCs may vary depending on ethnicity [47,48],  
416 to further understand the role of BMI in multimorbidity in these groups.

417

418

419

420

## 421 **Funding**

422 This work was supported by the UK Medical Research Council [grant number MR/W014548/1]. This  
423 study was supported by the National Institute for Health and Care Research (NIHR) Exeter Biomedical  
424 Research Centre (BRC), the NIHR Leicester BRC, the NIHR Oxford BRC, the NIHR Peninsula Applied  
425 Research Collaboration, and the NIHR Health Tech Research Centre. JM is funded by an NIHR Advanced  
426 Fellowship (NIHR302270). The views expressed are those of the authors and not necessarily those of  
427 the NIHR or the Department of Health and Social Care.

## 428 **Acknowledgements**

429 We acknowledge all members of the GEMINI Consortium. This includes researchers Olivia Murrin,  
430 Carlos Gallego-Moll, Albert Roso-Llorach, Lucía A Carrasco-Ribelles, Chris Fox, Louise M Allan, Xiaoran  
431 Liang, Ruby M Woodward, Deniz Türkmen, Kate Boddy, Jose M Valderas, Sara M Khalid, Sally E Lamb,  
432 David Melzer, and Concepción Violán, in addition to patient representatives Mary Mancini and Leon  
433 Farmer. The whole GEMINI team were central to developing the LTC definitions, observational  
434 associations in population representative primary care cohorts, genetic associations between LTC  
435 pairs, and developing and refining the research question(s) and results.

436 This research has been conducted using the UK Biobank Resource under Application Number 9072.  
437 We want to acknowledge the participants and investigators of the FinnGen study. We also thank the  
438 authors and study participants for the published GWAS consortium meta-analyses utilized in this  
439 report (see [11] and the project GitHub pages [<https://github.com/GEMINI-multimorbidity>] for details  
440 and citation). The authors would like to acknowledge the use of the University of Exeter High-  
441 Performance Computing (HPC) facility in carrying out this work.

## 442 **Disclosures**

443 JB is a part time employee of Novo Nordisk Research Centre Oxford, limited. TF has consulted for  
444 several pharmaceutical companies. All other authors have no disclosures to declare.

## 445 **Contributions**

446 Conceptualization: NM, LP, FD, TF, JB. Data Curation NM, BV, LP: Formal Analysis: NM, BV, LP. Funding  
447 Acquisition JM, JD, FD, LP, JB, TF. Interpretation: NM, BV, JM, JD, FD, LP, TF, JB. Investigation: NM, JB.  
448 Resources: NM, BV, LP. Software: NM Supervision: JB, TF, LP, FD. Writing – Original Draft: Writing – NM,  
449 LP, TF, JB. Review & Editing: NM, BV, JM, JD, FD, LP, TF, JB.

450

451 **References**

- 452 1. Marengoni A, Angleman S, Melis R, Mangialasche F, Karp A, Garmen A, et al. Aging with  
453 multimorbidity: A systematic review of the literature. *Ageing Res Rev.* 2011;10: 430–439.  
454 doi:10.1016/j.arr.2011.03.003
- 455 2. Johnston MC, Crilly M, Black C, Prescott GJ, Mercer SW. Defining and measuring  
456 multimorbidity: a systematic review of systematic reviews. *Eur J Public Health.* 2019;29: 182–  
457 189. doi:10.1093/eurpub/cky098
- 458 3. Ho ISS, Azcoaga-Lorenzo A, Akbari A, Davies J, Khunti K, Kadam UT, et al. Measuring  
459 multimorbidity in research: Delphi consensus study. *BMJ medicine.* 2022;1: e000247.  
460 doi:10.1136/bmjmed-2022-000247
- 461 4. Chowdhury SR, Chandra Das D, Sunna TC, Beyene J, Hossain A. Global and regional prevalence  
462 of multimorbidity in the adult population in community settings: a systematic review and  
463 meta-analysis. *EClinicalMedicine.* 2023;57: 101860. doi:10.1016/j.eclinm.2023.101860
- 464 5. Calderón-Larrañaga A, Vetrano DL, Onder G, Gimeno-Feliu LA, Coscollar-Santaliestra C, Carfi A,  
465 et al. Assessing and Measuring Chronic Multimorbidity in the Older Population: A Proposal for  
466 Its Operationalization. *J Gerontol A Biol Sci Med Sci.* 2017;72: 1417–1423.  
467 doi:10.1093/gerona/glw233
- 468 6. Zemedikun DT, Gray LJ, Khunti K, Davies MJ, Dhalwani NN. Patterns of Multimorbidity in  
469 Middle-Aged and Older Adults: An Analysis of the UK Biobank Data. *Mayo Clin Proc.* 2018;93:  
470 857–866. doi:10.1016/j.mayocp.2018.02.012
- 471 7. Ho IS-S, Azcoaga-Lorenzo A, Akbari A, Black C, Davies J, Hodgins P, et al. Examining variation in  
472 the measurement of multimorbidity in research: a systematic review of 566 studies. *Lancet*  
473 *Public Health.* 2021;6: e587–e597. doi:10.1016/S2468-2667(21)00107-9
- 474 8. Nichols L, Taverner T, Crowe F, Richardson S, Yau C, Kiddle S, et al. In simulated data and  
475 health records, latent class analysis was the optimum multimorbidity clustering algorithm. *J*  
476 *Clin Epidemiol.* 2022;152: 164–175. doi:10.1016/j.jclinepi.2022.10.011
- 477 9. Pathirana TI, Jackson CA. Socioeconomic status and multimorbidity: a systematic review and  
478 meta-analysis. *Aust N Z J Public Health.* 2018;42: 186–194. doi:10.1111/1753-6405.12762
- 479 10. Kivimäki M, Strandberg T, Pentti J, Nyberg ST, Frank P, Jokela M, et al. Body-mass index and  
480 risk of obesity-related complex multimorbidity: an observational multicohort study. *Lancet*  
481 *Diabetes Endocrinol.* 2022;10: 253–263. doi:10.1016/S2213-8587(22)00033-X
- 482 11. Murrin O, Mounier N, Voller B, Tata L, Gallego-Moll C, Roso-Llorach A, et al. A systematic  
483 analysis of the contribution of genetics to multimorbidity and comparisons with primary care  
484 data. *medRxiv.* 2024; 2024.05.13.24307009. doi:10.1101/2024.05.13.24307009
- 485 12. Kraft P, Chen H, Lindström S. The Use Of Genetic Correlation And Mendelian Randomization  
486 Studies To Increase Our Understanding of Relationships Between Complex Traits. *Curr*  
487 *Epidemiol Rep.* 2020;7: 104–112. doi:10.1007/s40471-020-00233-6
- 488 13. Dixon P, Hollingworth W, Harrison S, Davies NM, Davey Smith G. Mendelian Randomization  
489 analysis of the causal effect of adiposity on hospital costs. *J Health Econ.* 2020;70: 102300.  
490 doi:10.1016/j.jhealeco.2020.102300

- 491 14. van Rheenen W, Peyrot WJ, Schork AJ, Lee SH, Wray NR. Genetic correlations of polygenic  
492 disease traits: from theory to practice. *Nat Rev Genet.* 2019;20: 567–581.  
493 doi:10.1038/s41576-019-0137-z
- 494 15. Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal  
495 relationships inferred from Mendelian randomization between complex traits and diseases.  
496 *Nat Genet.* 2018;50: 693–698. doi:10.1038/s41588-018-0099-7
- 497 16. Larsson SC, Burgess S. Causal role of high body mass index in multiple chronic diseases: a  
498 systematic review and meta-analysis of Mendelian randomization studies. *BMC Med.*  
499 2021;19: 320. doi:10.1186/s12916-021-02188-x
- 500 17. World Health Organisation. International Statistical Classification of Diseases and Related  
501 Health Problems (ICD). 2019 [cited 1 Jul 2022]. Available: <https://icd.who.int/>
- 502 18. Recalde M, Rodríguez C, Burn E, Far M, García D, Carrere-Molina J, et al. Data Resource  
503 Profile: The Information System for Research in Primary Care (SIDIAPI). *Int J Epidemiol.*  
504 2022;51: e324–e336. doi:10.1093/ije/dyac068
- 505 19. Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, et al. Data Resource  
506 Profile: Clinical Practice Research Datalink (CPRD). *Int J Epidemiol.* 2015;44: 827–836.  
507 doi:10.1093/ije/dyv098
- 508 20. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK Biobank: An Open Access  
509 Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old  
510 Age. *PLoS Med.* 2015;12: e1001779. doi:10.1371/journal.pmed.1001779
- 511 21. Yengo L, Sidorenko J, Kemper KE, Zheng Z, Wood AR, Weedon MN, et al. Meta-analysis of  
512 genome-wide association studies for height and body mass index in ~700000 individuals of  
513 European ancestry. *Hum Mol Genet.* 2018;27: 3641–3649. doi:10.1093/hmg/ddy271
- 514 22. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, et al. Genetic studies of body mass  
515 index yield new insights for obesity biology. *Nature.* 2015;518: 197–206.  
516 doi:10.1038/nature14177
- 517 23. Bulik-Sullivan BK, Loh P-R, Finucane HK, Ripke S, Yang J, Patterson N, et al. LD Score regression  
518 distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet.*  
519 2015;47: 291–295. doi:10.1038/ng.3211
- 520 24. Bulik-Sullivan B, Finucane HK, Anttila V, Gusev A, Day FR, Loh P-R, et al. An atlas of genetic  
521 correlations across human diseases and traits. *Nat Genet.* 2015;47: 1236–41.  
522 doi:10.1038/ng.3406
- 523 25. Mounier N, Kutalik Z. bGWAS: an R package to perform Bayesian genome wide association  
524 studies. *Bioinformatics.* 2020;36: 4374–4376. doi:10.1093/bioinformatics/btaa549
- 525 26. Pirastu N, McDonnell C, Grzeszkowiak EJ, Mounier N, Imamura F, Merino J, et al. Using genetic  
526 variation to disentangle the complex relationship between food intake and health outcomes.  
527 *PLoS Genet.* 2022;18: e1010162. doi:10.1371/journal.pgen.1010162
- 528 27. Murad MH, Wang Z, Zhu Y, Saadi S, Chu H, Lin L. Methods for deriving risk difference (absolute  
529 risk reduction) from a meta-analysis. *BMJ.* 2023; e073141. doi:10.1136/bmj-2022-073141

- 530 28. Espallargues M, Sampietro-Colom L, Estrada MD, Solà M, del Río L, Setoain J, et al. Identifying  
531 Bone-Mass-Related Risk Factors for Fracture to Guide Bone Densitometry Measurements: A  
532 Systematic Review of the Literature. *Osteoporosis International*. 2001;12: 811–822.  
533 doi:10.1007/s001980170031
- 534 29. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of  
535 Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those  
536 of the General Population. *Am J Epidemiol*. 2017;186: 1026–1034. doi:10.1093/aje/kwx246
- 537 30. Kivimäki M, Strandberg T, Pentti J, Nyberg ST, Frank P, Jokela M, et al. Body-mass index and  
538 risk of obesity-related complex multimorbidity: an observational multicohort study. *Lancet*  
539 *Diabetes Endocrinol*. 2022;10: 253–263. doi:10.1016/S2213-8587(22)00033-X
- 540 31. Duclos M. Osteoarthritis, obesity and type 2 diabetes: The weight of waist circumference. *Ann*  
541 *Phys Rehabil Med*. 2016;59: 157–160. doi:10.1016/j.rehab.2016.04.002
- 542 32. Zeng Z, Jin T, Ni J, Huang L, Xie Y, He W, et al. Assessing the causal associations of obstructive  
543 sleep apnea with serum uric acid levels and gout: a bidirectional two-sample Mendelian  
544 randomization study. *Semin Arthritis Rheum*. 2022;57: 152095.  
545 doi:10.1016/j.semarthrit.2022.152095
- 546 33. Espallargues M, Sampietro-Colom L, Estrada MD, Solà M, del Río L, Setoain J, et al. Identifying  
547 Bone-Mass-Related Risk Factors for Fracture to Guide Bone Densitometry Measurements: A  
548 Systematic Review of the Literature. *Osteoporosis International*. 2001;12: 811–822.  
549 doi:10.1007/s001980170031
- 550 34. Carda S, Cisari C, Invernizzi M, Bevilacqua M. Osteoporosis after Stroke: A Review of the  
551 Causes and Potential Treatments. *Cerebrovascular Diseases*. 2009;28: 191–200.  
552 doi:10.1159/000226578
- 553 35. Chooi YC, Ding C, Magkos F. The epidemiology of obesity. *Metabolism*. 2019;92: 6–10.  
554 doi:10.1016/j.metabol.2018.09.005
- 555 36. Sulc J, Winkler TW, Heid IM, Kutalik Z. Heterogeneity in Obesity: Genetic Basis and Metabolic  
556 Consequences. *Curr Diab Rep*. 2020;20: 1. doi:10.1007/s11892-020-1285-4
- 557 37. Sulc J, Sonrel A, Mounier N, Auwerx C, Marouli E, Darrous L, et al. Composite trait Mendelian  
558 randomization reveals distinct metabolic and lifestyle consequences of differences in body  
559 shape. *Commun Biol*. 2021;4: 1064. doi:10.1038/s42003-021-02550-y
- 560 38. Martin S, Tyrrell J, Thomas EL, Bown MJ, Wood AR, Beaumont RN, et al. Disease  
561 consequences of higher adiposity uncoupled from its adverse metabolic effects using  
562 Mendelian randomisation. *Elife*. 2022;11. doi:10.7554/eLife.72452
- 563 39. Emerenziani S, Pier Luca Guarino M, Trillo Asensio L, Altomare A, Ribolsi M, Balestrieri P, et al.  
564 Role of Overweight and Obesity in Gastrointestinal Disease. *Nutrients*. 2019;12: 111.  
565 doi:10.3390/nu12010111
- 566 40. Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. *Lancet Oncol*. 2002;3:  
567 565–574. doi:10.1016/S1470-2045(02)00849-5
- 568 41. Silva Junior GB da, Bentes ACSN, Daher EDF, Matos SMA de. Obesity and kidney disease.  
569 *Jornal Brasileiro de Nefrologia*. 2017;39. doi:10.5935/0101-2800.20170011

- 570 42. Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T. Intentional weight loss  
571 and mortality among overweight individuals with diabetes. *Diabetes Care*. 2000;23: 1499–  
572 1504. doi:10.2337/diacare.23.10.1499
- 573 43. Liang X, Mounier N, Apfel N, Khalid S, Frayling TM, Bowden J, et al. Using clustering of genetic  
574 variants in Mendelian randomization to interrogate the causal pathways underlying  
575 multimorbidity. *medRxiv*. 2023; 2023.03.18.23287164. doi:10.1101/2023.03.18.23287164
- 576 44. Pulit SL, Stoneman C, Morris AP, Wood AR, Glastonbury CA, Tyrrell J, et al. Meta-analysis of  
577 genome-wide association studies for body fat distribution in 694 649 individuals of European  
578 ancestry. *Hum Mol Genet*. 2019;28: 166–174. doi:10.1093/hmg/ddy327
- 579 45. Censin JC, Peters SAE, Bovijn J, Ferreira T, Pulit SL, Mägi R, et al. Causal relationships between  
580 obesity and the leading causes of death in women and men. *PLoS Genet*. 2019;15: e1008405.  
581 doi:10.1371/journal.pgen.1008405
- 582 46. Heymsfield SB, Peterson CM, Thomas DM, Heo M, Schuna JM. Why are there race/ethnic  
583 differences in adult body mass index–adiposity relationships? A quantitative critical review.  
584 *Obesity Reviews*. 2016;17: 262–275. doi:10.1111/obr.12358
- 585 47. Colin Bell A. Ethnic Differences in the Association between Body Mass Index and  
586 Hypertension. *Am J Epidemiol*. 2002;155: 346–353. doi:10.1093/aje/155.4.346
- 587 48. Caleyachetty R, Barber TM, Mohammed NI, Cappuccio FP, Hardy R, Mathur R, et al. Ethnicity-  
588 specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based  
589 cohort study. *Lancet Diabetes Endocrinol*. 2021;9: 419–426. doi:10.1016/S2213-  
590 8587(21)00088-7
- 591
- 592 .